Thursday, October 29, 2020
Releviate™ Therapeutics, a bio-pharmaceutical company addressing the needs of patients suffering from chronic pain, signs an exclusive license for two patent pending human monoclonal antibodies developed by researchers at the University of California, Riverside and Duke University. Pre-clinical studies suggest the RLVT-9-01 (anti-MMP-9 antibody) and the RLVT-14-02 (anti-MMP-14 antibody) could directly target the specific matrix metalloproteinases (MMPs) activating neuropathic pain pathways. Extensive recent studies implicate MMP-9, MMP-14 and MMP-2 as causes of chronic pain.
“The University of California, Riverside is proud of its role in researching this scientific advancement, and we look forward to working with Releviate Therapeutics for its next phase of study and, potentially, patient care,” says Brian Suh, director of technology commercialization at the University of California, Riverside.